T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures

Elizabeth Tringham, Kim L. Powell, Stuart M. Cain, Kristy Kuplast, Janette Mezeyova, Manjula Weerapura, Cyrus Eduljee, Xinpo Jiang, Paula Smith, Jerrie Lynn Morrison, Nigel C. Jones, Emma Braine, Gil Rind, Molly Fee-Maki, David Parker, Hassan Pajouhesh, Manjeet Parmar, Terence J. O'Brien, Terrance P. Snutch

Research output: Contribution to journalArticleResearchpeer-review

101 Citations (Scopus)

Abstract

Absence seizures are a common seizure type in children with genetic generalized epilepsy and are characterized by a temporary loss of awareness, arrest of physical activity, and accompanying spike-and-wave discharges on an electroencephalogram. They arise from abnormal, hypersynchronous neuronal firing in brain thalamocortical circuits. Currently available therapeutic agents are only partially effective and act on multiple molecular targets, including γ-aminobutyric acid (GABA) transaminase, sodium channels, and calcium (Ca 2+) channels. We sought to develop high-affinity T-type specific Ca 2+ channel antagonists and to assess their efficacy against absence seizures in the Genetic Absence Epilepsy Rats from Strasbourg (GAERS) model. Using a rational drug design strategy that used knowledge from a previous N-type Ca 2+ channel pharmacophore and a high-throughput fluorometric Ca 2+influx assay, we identified the T-type Ca 2+ channel blockers Z941 and Z944 as candidate agents and showed in thalamic slices that they attenuated burst firing of thalamic reticular nucleus neurons in GAERS. Upon administration to GAERS animals, Z941 and Z944 potently suppressed absence seizures by 85 to 90% via a mechanism distinct from the effects of ethosuximide and valproate, two first-line clinical drugs for absence seizures. The ability of the T-type Ca 2+ channel antagonists to inhibit absence seizures and to reduce the duration and cycle frequency of spike-and-wave discharges suggests that these agents have a unique mechanism of action on pathological thalamocortical oscillatory activity distinct from current drugs used in clinical practice.

Original languageEnglish
Article number121ra19
Number of pages15
JournalScience Translational Medicine
Volume4
Issue number121
DOIs
Publication statusPublished - 15 Feb 2012
Externally publishedYes

Cite this